Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB12 vs Soliris in PNH
NCT04058158Phase 3Completed
- Sponsor
- Samsung Bioepis
- Start
- Aug 2019
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of SB12 in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Samsung Bioepis. Primary endpoints: Lactate Dehydrogenase at 26 weeks and Time-adjusted Area Under the Effect Curve of Lactate Dehydrogenase at 52 weeks. Started Aug 2019; status: completed.
02
Drugs
SB12
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04058158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04058158.